VENETOCLAX
Manufacturer: AbbVie Inc.
Score: 141.0
Venclexta (Venetoclax) is a BCL-2 inhibitor used for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), and in combination with azacitidine, decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. The drug has shown significant clinical activity in these indications, but also carries important safety risks, including tumor lysis syndrome, neutropenia, and infections. Dosing recommendations vary by indication and patient population, with a 5-week ramp-up phase for CLL/SLL and a 3- or 4-day ramp-up for AML. Special population considerations include use during pregnancy, pediatric use, and geriatric use.
Tumor lysis syndrome, neutropenia, and infections are important safety risks associated with Venclexta
Dose adjustments may be necessary for patients with neutropenia, thrombocytopenia, or other adverse reactions
20 mg on Week 1, 50 mg on Week 2, 100 mg on Week 3, 200 mg on Week 4, and 400 mg on Week 5 and beyond
100 mg on Day 1, 200 mg on Day 2, 400 mg on Day 3, and 400 mg or 600 mg on Days 4 and beyond